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Bleomycin A5 sclerotherapy for cervicofacial
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Objectives: The purpose of this study was to document the results of bleomycin A5 sclerotherapy for cervicofacial
lymphatic malformations (LMs), and the clinical data of 65 patients between October 2004 and October 2007 were
reviewed.
Methods: Of the 65 patients in the study, 60 patients were given intralesional injection of bleomycin A5. Five patients
underwent partial resection, and then an injection of bleomycin A5 for the remaining lesion. The outcomes were assessed
by physical examination and Doppler ultrasonography scan. The follow-up time was from 6 months to 3 years after the
last injection (mean, 16 months).
Results: Among the 65 patients, 41 were men and 24 were women (1.7:1 male:female ratio), the age range was 3 months
to 45 years (mean, 12 years). Thirty-two lesions (49%) were macrocystic, 30 (46%) were microcystic, and 3 (5%) were
combined. Each patient received 1 to 10 injections (mean, 3.0 injections) for the whole course of treatment, and the total
dose of bleomycin A5 was from 8 to 80 milligrams (mean, 24.0 mg). Twenty-six of 32 macrocystic lesions (81%) showed
greater than 90% reduction, whereas another 6 (19%) exhibited 50% to 90% reduction. Nineteen of 30 microcystic lesions
(63%) showed greater than 90% reduction; 10 (33%) had 50% to 90% reduction; and 1 (4%) had less than 50% size
reduction. Of the 3 combined lesions, 2 (67%) had greater than 90% shrinkage, and 1 (3%) had less than 50% reduction.
The complications included ulceration of oral mucosa, minor soft tissue atrophy, mild fever, and hematoma. There was
no recurrence throughout the follow-up period.
Conclusion: These data suggest bleomycin A5 is a safe and effective intralesional agent for the treatment of macrocystic
LMs, superficial oral mucosa LM, and localized deep microcystic lesions. For extensive macrocystic LMs involving
contiguous anatomic areas and diffuse microcystic lesions involving deep tissues, bleomycin A5 injection combined with
resection is necessary. ( J Vasc Surg 2011;53:150-5.)Lymphatic malformations (LMs) are developmental
anomalies consisting of abnormally formed lymphatic
channels and cystic spaces of varying size. Histologically,
the vascular spaces are filled with eosinophilic, protein-rich
fluid. A single layer of flattened endothelium lines the
channels and the walls are composed of abnormally formed
smooth and skeletal muscular elements.1 There are three
morphologic types of LMs: microcystic, macrocystic, and
combined (combination of microcystic and macrocystic
components). Macrocystic LMs are comprised of single or
multiloculated cysts that vary in size and are filled with
lymphatic fluid; they manifest as soft, compressible or non-
compressible, translucent masses. Microcystic LMs are
comprised of abnormal lymphatic tissue with a variable
fibrous/fatty component, tiny cysts, or ectatic channels.2
More than 70% of LMs are located in the head and
neck. These cervicofacial lesions can involve oral mucosa,
skin, subcutaneous tissue, muscles, and the maxillofacial
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150bones. LMs cause pain, bleeding, infection, muscular atro-
phy, malocclusion, speech difficulties, feeding problems,
airway obstruction, and cosmetic deformities. Spontaneous
regression of LMs sometimes occurs, typically as macrocys-
tic lesions in the posterior cervical triangle.3
Several methods have been used to treat LMs, includ-
ing surgical excision,4-6 sclerotherapy,7 laser therapy,8,9
and radiofrequency ablation.10,11 Resection is the tradi-
tional method; however, complete excision is usually not
possible. Infiltration into adjacent tissue and incomplete
resection result in a high recurrence rate. There are also
postoperative complications, such as inadvertent nerve in-
jury, airway obstruction caused by swelling, hematoma
formation, wound infection, and hypertrophic scarring.
Because of the relatively high morbidity associated with
resection, sclerotherapy has assumed a more prominent
role in recent years. A variety of sclerosing agents have been
used, including OK-432, bleomycin, doxycycline, sodium
tetradecyl sulfate 3%, ethanol, alcoholic solution of zein,
fibrin sealant, polidocanol, sodium morrhuate, and acetic
acid.2,12-19
Bleomycin was first developed as an antineoplastic an-
tibiotic in 196620; its mechanism of action is inhibition of
DNA synthesis21; its sclerosing effect was discovered later.
The mechanism involves damage to endothelial cells with a
nonspecific inflammatory reaction and occlusion of vessels. It
was initially reported in 1977 for the treatment of cystic LMs
by Yura et al.14 They reported effective results in macrocystic
LMs. In this study, we present our experience with bleomycin
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Tianjin, China) sclerotherapy in the treatment of macrocystic,
microcystic, and incompletely resected LMs.
METHODS
Sixty-five patients with LM in cervicofacial regions were
treated between October 2004 and October 2007. The
diagnosis was confirmed by reviewing each patient’s medi-
cal history, conducting a physical examination, Doppler
ultrasonography scan, and magnetic resonance imaging.
LMs were classified as either macrocystic, microcystic, or
combined (both macrocystic and microcystic compo-
nents). The lesions were separated into local and diffuse
categories based on the anatomic locations. We defined
diffuse lesions as involving oral mucosa and deep tissues,
and cervicofacial areas, unilateral or bilateral.
Sixty patients received only intralesional bleomycin A5.
Five patients initially had partial resection, then injection of
bleomycin A5 into residual lesions. For most patients, the
procedure was performed routinely under regional anesthe-
sia in the office therapeutic room. For others, the procedure
was carried out under sedation or general anesthesia in the
operating room. For macrocystic and cystic components of
combined LMs, 8 mg bleomycin A5 powder was dissolved
in 3 mL lidocaine (2%, 2 mL) and dexamethasone (5 mg, 1
mL). Injection was performed through a 21-gauge needle.
After aspiration of lymphatic fluid, the needlewas kept in place
and the bleomycin A5 solution was injected into the cystic
cavities. For the sclerosis of microcystic LMs involving oral
mucosa or subcutaneous tissue, bleomycin A5 (8mg) powder
was dissolved in 3 to 5mL lidocaine (2%) and dexamethasone
(5 mg, 1 mL). The drug was injected directly and infiltrated
into the abnormal tissue. Ultrasonic guidance was used for
injection of deep lesions. The drug dose, drug concentration,
Table I. Anatomic location of macro and microcystic
lymphatic malformations in 65 patients




















Multiple/bilateral 2 (3.1)and treatment interval was adjusted according to the lesionalsize, location, classification, and response to therapy. Dexa-
methasone was used to reduce the possibility of allergic reac-
tion caused by bleomycin A5. Repeat injections were typically
performed at 2 to 3 week intervals.
Clinical manifestations, imaging characteristics, and
therapeutic outcomes were reviewed. The results were as-
sessed by a panel of three independently based oral sur-
geons who were given data from the clinical follow-up,
photographs, and Doppler ultrasonography scans. The
three oral surgeons directly examined the patients, and
measured and calculated lesion size. Only two post-
treatment lesions (the lesions located on the surface of the
oral mucosa) were evaluated by photographs because the
patients could not come to the clinic. A flexible tape was
used to measure maximal length and width above the
visible or palpable lesion surface. Lesion size was estimated
by calculating its surface area. For the deep lesions, the
lesion size was evaluated by the 2-dimensional scanning of
Doppler ultrasonography scan. The area of the lesion was
calculated by the maximal length and width. The response
rate was graded as follows: reduction greater than 90%,
Fig 1. Microcystic lymphatic malformation (LM) in the tongue.
A, Before treatment. B, After four bleomycin A5 injections.reduction of 50% to 90%, and reduction less than 50%. The
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treatment and the mean follow-up time was 16 months.
RESULTS
Of the 65 patients, 41 were men and 24 were women
(1.7:1male:female ratio), the age range was 3months to 45
years (mean, 12 years). Thirty-two lesions (49%) were
macrocystic, 30 (46%) were microcystic, and 3 (5%) were
combined. Anatomic areas involved by LM are summarized
in Table I. The size of the lesions treated by sclerotherapy
was 5.4 to 103.7 cm2 (mean, 19.2 cm2). Each patient
received 1 to 10 injections (mean, 3.0 injections) for the
whole course of treatment. Total dose of bleomycin A5
administered was 8 to 80 milligrams (mean, 24 mg).
The outcome in typical cases is shown in Figs 1 to 4.
Results were classified by cystic morphology of the LMs
(Table II). Macrocystic LMs exhibited the most shrinkage.
The complications included ulceration of oral mucosa
(n  4), slight soft tissue atrophy (n  1), mild fever (n 
2), and hematoma (n  1). Transient complications were
mainly swelling and pain. There were no allergic reactions,
Fig 2. Microcystic lymphatic malformation (LM) in th
After six bleomycin A5 injections.pulmonary fibrosis, nerve injury, or other complicationsduring or after the course of treatment. There was no
recurrence throughout the follow-up period.
DISCUSSION
LMs are present at birth but are not always obvious.
Most become evident before 2 years of age. LMs occur in any
part of the body, but are most commonly seen in lymphatic
dense areas, such as the cervicofacial region, axilla/chest,
mediastinum, retroperitoneum, buttock, and anogenital re-
gion.1 Typical lesions in the superficial oralmucosamanifest as
multiple fluid-filled and tiny clear or red vesicles. The lesions
usually involve the surface of the oral mucosa or submucosal
area but do not involve the muscles and subcutaneous tissue.
Extensive and deep involvement of lingual LM is the common
cause ofmacroglossia. Cutaneous vesicles rarely occur in facial
skin. The extensive macrocystic and microcystic LMs involv-
ing deep dermal and subcutaneous tissue can result in remark-
able cervicofacial deformity caused by thickening and swelling
of adjacent tissue.
Surgical excision has been the traditional approach for
LMs.4-6 The results are good for LMs that are macrocystic
er and lower lips. A and B, Before treatment. C and D,e uppand well demarcated. The outcome after resection of exten-
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pointing. These large lesions are frequently poorly defined
without distinct tissue planes between the abnormal and nor-
mal structures. Therefore, it is usually impossible to precisely
dissect and completely resect these lesions. Severe edema in
the oral floor and parapharyngeal region can follow attempts
at surgical excision of an extensive macrocystic LM, resulting
in airway obstruction and asphyxia.
Problems after resection of LMs have prompted explo-
ration of nonsurgical therapies. A laser has been used for
cutaneous and mucosal lesions8,9; however, the recurrence
rate is relatively high. Recently, radiofrequency ablation has
been successfully used for the control of microcystic LMs in
the oral cavity.10,11,22 This technique is safe and relatively
effective, but further studies are needed to assess long-term
control.
Sclerotherapy is considered to be the most effective
treatment of LMs. Various sclerosing agents have been
used (eg, alcoholic solution of zein,17 fibrin sealant,18 3%
sodium tetradecyl sulfate,2 and acetic acid).19 Doxycycline
Fig 3. Microcystic lymphatic malformation (LM) in the cheek
involving both buccal mucosa and deep tissue. A, Before treat-
ment. B, After four bleomycin A5 injections.is extensively used in the United States for macrocysticFig 4. Macrocystic lymphatic malformation (LM) involving sub-
mandibular, upper neck, and parotid areas.A,Before treatment.B,
T2-weighted magnetic resonance imaging on axial plane showing
a multiloculated high intensity signal. C, After four bleomycin A5
injections.
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possible efficacy for microcystic LMs. OK-432 was intro-
duced by Ogita et al12 in 1987 and is also a commonly used
sclerosing agent. It consists of bacterial components of an
avirulent strain of group A streptococcus pyogenes. Injec-
tion of OK-432 can cause endothelial damage/death and
shrinkage of LMs. OK-432 has shown good to excellent
responses in the majority of patients13; however, other
reports have shown that microcystic LMs respond poorly or
not at all to OK-432.24-26
Bleomycin is another agent for sclerotherapy, especially
for macrocystic LMs.14,15,27,28 Okada et al29 studied tis-
sues in patients who were given bleomycin injections pre-
operatively, and found the absence of normal lymphatic
epithelial lining, prominent infiltration of lymphocytes,
other inflammatory cells, and marked proliferation of stro-
mal connective tissue. Pingyangmycin is a similar com-
pound isolated from Streptomyces pingyangensisn cul-
tures,30 the major active component of which is bleomycin
A5. Bleomycin A5 is often used in China for treatment of
squamous cell carcinoma, and for venous malforma-
tions31 and LMs.32,33
We found that intralesional bleomycin A5 was reason-
ably effective in shrinking both macrocystic andmicrocystic
LMs. More than 81% of the macrocystic lesions and nearly
63% of the microcystic lesions exhibited greater than 90%
size reduction. In the past, bleomycin injection was mostly
used for treatment of macrocystic LMs. We also noted that
part of the microcystic LMs, especially if involving superfi-
cial oral mucosa had a favorable response to bleomycin A5.
All of the oral mucosal lesions disappeared after sclerother-
apy. Only 2 of the 65 lesions responded poorly to the
treatment with less than 50% reduction. One patient had a
diffuse bilateral microcystic lesion involving the submental
and submandibular region, and the other had combined
LM with predominantly microcystic lesions involving the
tongue, bilateral cheek, and right submandibular region.
The common characteristics of these 2 patients are that
they both had diffuse microcystic lesions involving contig-
uous anatomic areas and deep tissue. For the 2 patients, we
plan to give partial resection and then sclerotherapy later.
The procedures may be repeated several times.
Based on the results in our patients, we recommend
bleomycin A5 injection as the first-line therapy for most










Macrocystic 26 (81) 6 (19)
Microcystic 19 (63) 10 (33) 1 (4)
Combined 2 (67) 1 (33)
Total 47 (72) 16 (25) 2 (3)
LM, Lymphatic malformation.macrocystic LMs. We also use bleomycin A5 injection asthe primary treatment for the superficial oral mucosa LM.
Some lesions are scarred due to the repeated infection. For
this type of lesion, it is difficult to aspirate the lymphatic fluid
from the lesion and inject the sclerosing agent into the intralu-
minal space of the lesion. The drug is injected directly and
infiltrates into the area of abnormal tissue. The injection must
be at high pressure until the surface turns pale and rupture of
the vesicles can be seen. There is always concern about extrav-
asation of a sclerosant and possible damage to adjacent tissue.
Oralmucosal ulceration occurred in 4 patients, but the lesions
disappeared completely after healing of the ulceration.
Some relatively localized deep microcystic lesions in-
volving the lips or cheeks also responded well to the bleo-
mycin A5 injection. The possible complication is soft tissue
atrophy; 1 patient in our series had minor atrophy of the
upper lip. The appropriate drug dosage and concentration
should be used when injecting labial lesions. For the chil-
dren with microcystic LMs lesions in the lips, we suggest
the lower dosage, lower concentration, and longer intervals
between injections. For instance, bleomycin A5 (8 mg)
powder is dissolved in 5 mL of lidocaine (2%) and dexa-
methasone (5 mg, 1 mL). The drug dosage was less than 5
mg for every injection. The interval time was extended to 1
to 2 months.
Bleomycin A5 sclerotherapy was also useful for residual
unresectable lesions. Five of 65 patients first underwent partial
surgical resection, and then bleomycin A5 sclerotherapy. The
injection of bleomycin A5 near the facial nerve did not cause
injury. The total dose of bleomycin administered to the pa-
tients is of concern. Excessive use of large doses of bleomycin
A5may increase the risk of pulmonary fibrosis. Partial surgical
resection can reduce the volume of the lesions, and as a result,
reduce the dose of sclerosing agent needed. This combined
approach is ofmajor benefit to patientswith a large diffuseLM
that will require a large dose of sclerosing agent to accomplish
the whole course of treatment.
There are several options for the treatment of extensive
LMs in our department: partial resection and then sclerother-
apy, sclerotherapy first and then surgical resection, and re-
peated sclerotherapy and surgical resection. It mainly depends
on the patients’ age, and the location, size, and type of the
lesions. In the current series, themain purpose was to evaluate
the effects of bleomycin A5 sclerotherapy for LMs and incom-
pletely resected LMs, so we did not choose the patients with
sclerotherapy first and then surgical resection. That did not
meanwe suggested that every patient underwent partial resec-
tion first and then injection of bleomycinA5.Webelieved that
the sclerosing agent was injected first and then surgical resec-
tion was a good option for some lesions.
Previously reported complications of intralesional bleo-
mycin A5 include fever, ulceration, anorexia, vomiting, and
cellulitis.27,29,32,33 Pulmonary fibrosis occasionally arises in
the patients after administration of a large dose, such as
needed for patients with a malignant tumor.34 Hypersen-
sitivity reactions are rare, but are potentially fatal.35We used 5
mg dexamethasone with each bleomycin A5 injection to pre-
vent possible allergic reaction. In our series, besides ulceration
of oral mucosa and soft tissue atrophy, the other complica-
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with upper neck and parotid macrocystic LM.
CONCLUSIONS
These data suggest intralesional injection of bleomycin
A5 is safe and effective for the treatment of macrocystic
LMs, superficial oral mucosal LMs, and relatively localized
deep microcystic lesions. For the extensive macrocystic
LMs involving multiple anatomic areas and diffuse micro-
cystic lesions involving deep tissue, bleomycin A5 injection
combined with surgical excision is recommended.
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